INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced ≥grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population.
INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS:Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced ≥grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population.
Authors: P A Zucali; G L Ceresoli; F De Vincenzo; M Simonelli; E Lorenzi; L Gianoncelli; A Santoro Journal: Cancer Treat Rev Date: 2011-02-01 Impact factor: 12.111
Authors: Sarita Dubey; Pasi A Jänne; Lee Krug; Herbert Pang; Xiaofei Wang; Robin Heinze; Colleen Watt; Jeff Crawford; Robert Kratzke; Everett Vokes; Hedy Lee Kindler Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Sound Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc de Perrot; Geoffrey Liu Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Marwa Ali A Fathi; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Samar H Abbas; Monica M Montano; Mohamed Abdel-Aziz Journal: Bioorg Chem Date: 2018-11-22 Impact factor: 5.275
Authors: Andrew M Brunner; Daniel B Costa; Rebecca S Heist; Elizabeth Garcia; Neal I Lindeman; Lynette M Sholl; Geoffrey R Oxnard; Bruce E Johnson; Peter S Hammerman Journal: J Thorac Oncol Date: 2013-11 Impact factor: 15.609
Authors: Jie Huang; Wei Hu; Justin Bottsford-Miller; Tao Liu; Hee Dong Han; Behrouz Zand; Sunila Pradeep; Ju-Won Roh; Duangmani Thanapprapasr; Heather J Dalton; Chad V Pecot; Rajesh Rupaimoole; Chunhua Lu; Bryan Fellman; Diana Urbauer; Yu Kang; Nicholas B Jennings; Li Huang; Michael T Deavers; Russell Broaddus; Robert L Coleman; Anil K Sood Journal: Clin Cancer Res Date: 2014-01-31 Impact factor: 12.531